TAVR by Edwards provides lasting clinical benefits1,2

TAVR by Edwards at 1 year in low-risk patients


experienced freedom from death, disabling stroke, and rehospitalization due to heart failure1


experienced freedom from a new pacemaker after receiving TAVR1

SAPIEN 3 TAVR was studied in the PARTNER 3 Trial.1

The primary endpoints were all-cause death, stroke, and rehospitalization at 1 year, with multiple prespecified secondary endpoints in low-risk patients.1

SAPIEN 3 Transcatheter Heart Valve System and SAPIEN 3 Ultra TAVR involve serious risks, including death, stroke, major bleeding, and major vascular complications.

In a study of real-world patients

The Edwards SAPIEN 3 Ultra valve demonstrated excellent paravalvular leak (PVL) performance

87% visual representing percent of patients who saw no/trace PVL in an RWE study

saw no/trace PVL at 30 days3

100% visual representing percent of recipients who experienced successful post-TAVR coronary access

of recipients experienced successful post-TAVR coronary access4


Only TAVR by Edwards heart valves are approved for TAVR-in-TAVR procedures

For patients assessed at high risk for surgical valve replacement.

TAVR was proven superior to SAVR at 1 year—and equally as
effective at 5 years1,2

At 5 years, TAVR demonstrated comparable results vs SAVR

Chart of cardiovascular and all-cause mortality rates, disabling stroke and stroke rates, and hospitalization rates of TAVR vs. SAVR

The PARTNER 3 Trial, SAPIEN 3 TAVR was proven superior to surgery on the primary endpoint of all-cause death, all stroke, and re-hospitalization (valve-related or procedure-related and including heart failure) at one year, and multiple pre-specified secondary endpoints in low risk patients.1

PARTNER 3 Trial 5-Year Results in low-risk patients – Low rates of cardiovascular mortality through five years (5.5% SAPIEN 3 TAVR to 5.1% SAVR). Low rates of all-cause mortality through five years (10.1% SAPIEN 3 TAVR vs. 8.2% with SAVR). Low rates of disabling stroke through five years (2.9% SAPIEN 3 TAVR to 2.7% SAVR). Low rates of stroke through five years (5.8% SAPIEN 3 TAVR vs. 6.4% SAVR). Lower rates of rehospitalization with SAPIEN 3 TAVR through five years (13.7% vs. 17.4%).2

SAPIEN 3 valves are designed with your patients' future in mind, offering a comprehensive approach to durability5

Over the past decade, TAVR has become the preferred treatment for patients with symptomatic severe aortic stenosis (sSAS). At 10 years, 98% of TAVR recipients did not require valvular reintervention.*6,8

Rick, a real TAVR patient, talking with a cardiologist


Download the TAVR Info Kit, which contains details about the procedure.



Find helpful videos, downloads, and links to relevant websites.

*When accounting for death as a competing risk.

References: 1.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. 2.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949-1960. 3.Nazif TM, Cahill TJ, Daniels D, et al. Real-world experience with the SAPIEN 3 Ultra transcatheter heart valve: a propensity-matched analysis from the United States. Circ Cardiovasc Interv. 2021;14(9):e010543. 4.Tarantini G, Nai Fovino L, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13(7):e008972. 5.Rheude T, Blumenstein J, Möllmann H, Husser O. Spotlight on the SAPIEN 3 transcatheter heart valve. Med Devices (Auckl). 2018;11:353-360. Published 2018 Oct 1. 6.Madhavan MV, Kodali SK, Thourani VH, et al. Outcomes of SAPIEN 3 transcatheter aortic valve replacement compared with surgical valve replacement in intermediate-risk patients. J Am Coll Cardiol. 2023;82(2):109-123. 7.Flameng W, Hermans H, Verbeken E, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149(1):340-345. 8.Baron SJ, Ryan MP, Chikermane SG, Thompson C, Clancy S, Gunnarsson CL. Long-term risk of reintervention after transcatheter aortic valve replacement. Am Heart J. 2024;267:44-51.

Patients and/or clinicians quoted on this website have received compensation from Edwards Lifesciences.